[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medical College of Wisconsin\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":657},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,120,0,25,[9,50,75,98,122,151,173,198,227,252,278,300,332,353,375,400,421,454,479,513,546,564,589,612,633],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053795","language-processing-and-tms-100053795",false,"NCT05425615","Language Processing and TMS","Probing Language Processes Using Transcranial Magnetic Stimulation","Inclusion Criteria:\n\n* Diagnosed with left hemisphere stroke\n* Consent date \\>= 1 month after stroke onset\n* Right-handed\n* Fluent in English\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Severe cognitive, auditory or visual impairments that would preclude cognitive and language testing\n* Non-decisional per decisionality questionnaire or other clinical assessment\n* Presence of major untreated or unstable psychiatric disease (e.g. schizophrenia, bipolar disease)\n* A chronic medical condition that is not treated or is unstable\n* Presence of\n\n  1. cardiac stimulators or pacemakers or intracardiac lines\n  2. neurostimulators\n  3. medication infusion device\n  4. any other implants near the scalp (e.g., cochlear implants) or in the eye\n  5. metal in the body\n* Pregnancy\n* History of skull fractures, or skin diseases\n* History of ongoing or unmanaged seizures or a family history of epilepsy\n* Presence of factors that potentially decrease seizure thresholds\n* On pro-convulsant medications\n* Untreated Sleep deprivation or insomnia\n* Ongoing alcoholism or illegal drug abuse (e.g., cocaine or MDMA users)\n* History of dyslexia or other developmental learning disabilities",true,"ALL","18 Years","85 Years",{"count":22,"type":23},135,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study will examine the effect of TMS on people with stroke and aphasia as well as healthy individuals.",[29,30,31],"Stroke","Aphasia","Language",[33,34,30,35,36],"TMS","Transcranial Magnetic Stimulation","Semantic processing","Phonological processing","RECRUITING","2026-07-09",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2024-06-05",{"date":45,"type":23},"2032-06",{"name":47,"class":48},"Medical College of Wisconsin","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100053907","hybrid-group-singing-100053907","NCT07355192","Hybrid Group Singing","Group Singing (Hybrid Format) or Solo Singing in Older Adults With Coronary Artery Disease: A Feasibility Study","Inclusion Criteria:\n\n* history of coronary artery disease (defined as having at least 1 of the following: myocardial infarction, coronary stent, PCI, CABG, coronary stenosis at least 50%, or coronary artery calcification score at least 300 Agatston units)\n\nExclusion Criteria:\n\n* Parkinson's disease or tremor\n* upper arm fistula\n* fingernail onychomycosis\n* pregnancy\n* current tobacco use\n* current illicit drug use\n* current excessive alcohol use (defined as more than 14 drinks\u002Fweek for women, more than 28 drinks\u002Fweek for men)\n* unstable CAD (active symptoms of chest discomfort)\n* supplemental oxygen use\n* more than mild cognitive impairment (as documented in the medical record by patient's treatment teams)\n* inability to follow study procedures\n* non-English speaking","55 Years","89 Years",{"count":60,"type":23},32,[26],"The overall objective of the planned future clinical trial is to test the investigator's central hypothesis that habitual singing over several weeks, similar to habitual exercise, will lead to sustained and favorable vascular adaptation, thereby lowering cardiovascular disease (CVD) risk. The overall objective of this study is to refine and protocolize the singing interventions and test the feasibility of the future trial design. The investigative team has previously studied solo singing. Collective singing, as in a choir or small group, is associated with a positive sense of social inclusion, well-being, and improved mood, including in older adults.",[64,65],"Coronary Artery Disease","Elderly",[67,68],"group singing","individual singing",{"date":40,"type":41},{"date":71,"type":41},"2026-05-11",{"date":73,"type":23},"2028-02",{"name":47,"class":48},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":49},"100053811","transcranial-alternating-current-stimulation-tacs-in-aphasia-100053811","NCT04375722","Transcranial Alternating Current Stimulation (tACS) in Aphasia","Exogenous Tuning of Neural Oscillations as a Mode of Treatment in Post-stroke Aphasia","Inclusion Criteria:\n\nHealthy Controls\n\n* 18 years of age or older\n* Fluent in English\n* No history of neurological or psychiatric disorders\n\nStroke Patients\n\n* Diagnosed with post-stroke aphasia by referring physician\u002Fneuropsychologist\n* Consent date \\>=1 months after stroke onset\n* Right-handed\n* Fluent in English\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Severe cognitive, auditory or visual impairments that would preclude cognitive and language testing\n* Presence of major untreated or unstable psychiatric disease\n* A chronic medical condition that is not treated or is unstable\n* The presence of cardiac stimulators or pacemakers\n* Any metal implants in the skull\n* Contraindications to MRI or tACS\n* History of seizures\n* History of dyslexia or other developmental learning disabilities",{"count":83,"type":23},50,[26],"This study will assess the effects of transcranial alternating current stimulation (tACS) on language recovery after stroke as well as healthy language functions.",[30,29],[88,89,90,91],"language","language impairment","transcranial alternating current stimulation","tACS",{"date":40,"type":41},{"date":94,"type":41},"2020-01-04",{"date":96,"type":23},"2030-12",{"name":47,"class":48},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":24,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":49},"100462395","high-dose-re-irradiation-utilizing-advanced-deformable-image-registration-dir-and-individualized-organ-at-risk-oar-dose-calculations-with-organ-specific-toxicity-analysis-100462395","NCT05301101","High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis","High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis (REDIRICT)","REDIRICT","Inclusion Criteria:\n\n1. Provision of signed informed consent\n2. Patients ≥18 years of age receiving definitive or postoperative high dose radiation to volume that includes overlap with previously irradiated OAR(s).\n3. Prior radiation dosimetry must be available.\n4. Participants must have stage I-IV biopsy proven solid malignancy (histologic proof or unequivocal cytologic proof solid tumor malignancy from either the primary or any metastatic site). Documentation of pathology reports are required. Local review of pathology or cytology is at the discretion of the multidisciplinary team.\n5. Histologic confirmation of target lesion recurrence is recommended.\n6. Documentation of consensus for recommendation of reirradiation by multidisciplinary team and location of target lesion or postoperative site to be treated.\n7. Documentation of whether or not concurrent cancer therapy drugs are recommended and rationale.\n8. Documentation of rationale for not obtaining tissue confirmation of the target lesion, if applicable.\n9. Baseline target lesion imaging with CT, positron emission tomography (PET) \u002FCT, or MRI is required within six weeks of trial enrollment. CT or MRI simulation scans may be used for baseline imaging.\n10. Patients who have had disease resected in a previously irradiated field and are at high pathological and clinical risk for recurrence as defined by the treating Radiation Oncologist and multidisciplinary team, are eligible for study.\n11. Measurable disease is not required for patients being treated postoperatively.\n12. Baseline labs are per standard practice. Values will be dependent on the OARs being treated. (Per standard practice, radiation therapy volumes to OARs are modified to accommodate compromised renal, liver, pulmonary or other OAR function). Recommended labs and values include:\n\n    * Aspartate transaminase (AST) and alanine transaminase (ALT) \\\u003C 2.5 x upper limit of normal (ULN) or \\\u003C 5 x ULN with metastatic liver disease.\n    * Total bilirubin \\\u003C 1.5 x ULN\n    * Absolute neutrophil count (ANC) \\> 500 cells\u002Fmm\\^3\n    * Platelets \\> 50,000 cells\u002Fmm\\^3\n    * Creatinine \\\u003C 1.5 x ULN or Creatinine clearance \\> 45 mL\u002Fmin if creatinine is \\> 1.5 x ULN (calculated Creatinine Clearance (CrCl) based on Cockcroft-Gault equation)\n13. Eastern Cooperative Oncology Group (ECOG) Performance Score 0-2.\n14. Patients must have resolution of acute toxic effect(s) of most recent cancer therapy to Grade 1 or 2.\n15. Life expectancy of at least 6 months.\n16. Female patients of childbearing potential must have negative urine or serum pregnancy test within 7 days prior to start of re-irradiation.\n17. Ability to complete the self-reported questionnaires (translations will be made available if the patient's primary language is not English).\n18. Concurrent participation on pharmaceutical, investigator-initiated, National Clinical Trials Network (NCTN), or other multisite clinical trials that include re-irradiation is allowed.\n\nExclusion Criteria:\n\n1. Patients receiving low dose radiation for symptom management only.\n2. Patients with evidence of severe or uncontrolled systemic conditions.\n3. Life expectancy of less than 6 months.\n4. ECOG Performance status ≥ 3.\n5. Women of childbearing potential who are known to be pregnant or are unwilling to use an acceptable method of contraception from the time of informed consent until completion of the course of radiotherapy",{"count":5,"type":23},[26],"This trial applies a uniform approach to re-irradiation for planning and diagnostic image fusion, dose summation, dose calculations, and follow up for tumor control and detailed toxicity analysis of serial Organs At Risk (OARs). Serial organs include named arteries and nerves, spinal cord, and gastrointestinal tract.",[110],"Solid Tumor",[112,113],"high dose radiation","re-irradiation","2026-06-26",{"date":116,"type":41},"2026-06-30",{"date":118,"type":41},"2022-06-13",{"date":120,"type":23},"2028-07",{"name":47,"class":48},{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":24,"phases":131,"briefSummary":133,"conditions":134,"keywords":139,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":49},"100636995","phase-2-a-pragmatic-clinical-trial-to-prevent-relapse-for-myeloid-malignancies-with-measurable-disease-prior-to-allogeneic-transplant-100636995","NCT07572929","A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant","PREeMPT","Inclusion Criteria:\n\n* Age ≥18 years at time of transplant.\n* Must have a diagnosis of a myeloid malignancy, myelodysplastic syndrome, myeloproliferative neoplasm (including primary or secondary myelofibrosis), or acute myeloid leukemia or biphenotypic acute leukemia.\n* Pre-transplant disease assessment must include at least one:\n* Immunophenotypic assessment by flow for aberrant blasts\n* NGS to identify persistence of malignant clones using a standard clinically available assay\n* PCR based measurement of prior identified mutations (if applicable)\n* Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\nNone",{"count":130,"type":23},450,[132],"PHASE2","This is a prospective, open-label investigation to determine whether measurable residual disease (MRD) guided assignment of maintenance therapy is effective in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT). Pre-HCT, patients will undergo usual disease assessments which should include immunophenotypic and\u002For molecular testing. Based on the results of these tests, patients may or may not be recommended to receive maintenance therapy post-transplant, depending on the presence or absence of a residual malignant clone.",[135,136,137,138],"Myeloid Disorders","Myelodysplastic Syndromes","Myeloproliferative Neoplasm","Acute Myeloid Leukemia",[140,141],"Allogeneic hematopoietic cell transplantation","Measurable residual disease","NOT_YET_RECRUITING","2026-06-19",{"date":145,"type":41},"2026-06-23",{"date":147,"type":23},"2026-08-01",{"date":149,"type":23},"2034-02-01",{"name":47,"class":48},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":172},"100601948","blinatumomab-consolidation-in-real-world-100601948","NCT07117136","Blinatumomab Consolidation in Real World","Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* 1\\) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2023 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients\n\nExclusion Criteria:\n\n* N\u002FA",{"count":159,"type":23},200,"OBSERVATIONAL","This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \\& Translational Science Institute.",[163],"B-Cell Acute Lymphoblastic Leukaemia","2026-06-16",{"date":166,"type":41},"2026-06-18",{"date":168,"type":41},"2025-08-28",{"date":170,"type":23},"2029-05-14",{"name":47,"class":48},2,{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":24,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":49},"100563987","a-clinical-trial-of-the-administration-of-light-therapy-to-prevent-mouth-sores-in-children-with-cancer-100563987","NCT06623305","A Clinical Trial of the Administration of Light Therapy to Prevent Mouth Sores in Children With Cancer","Photobiomodulation Therapy for the Prevention of Mucositis in Pediatric Oncology Patients","PBM","Inclusion Criteria:\n\n1. Current and new diagnosis patients consented upon admission if deemed eligible\n2. Ages 0-30\n3. Admitted to CW oncology\u002FBMT inpatient unit, PICU, or West 5\n4. Chemotherapy regimen: Methotrexate ≥5 g\u002Fm2 (or ≥1 g\u002Fm2 if Trisomy 21) OR Anthracycline ≥60 mg\u002Fm2\n5. Able to speak and understand English or Spanish\n\nExclusion Criteria:\n\n1. Patients admitted on BMT service\n2. Patients currently experiencing mucositis with a CTCAE grade 4 oral mucositis or higher","30 Years",{"count":83,"type":23},[26],"The goal of this clinical trial is to learn if light therapy can prevent mouth sores in children with cancer. The main questions it aims to answer are:\n\nIs it reasonable and acceptable to provide light therapy for children with cancer?\n\nDoes light therapy prevent mouth sores related to medical treatment?\n\nResearchers will compare children who do not receive light therapy to children who do receive light therapy during the clinical trial to see if light therapy helps to prevent mucositis.\n\nParticipants will:\n\n* Complete a survey.\n* Have picture taken of their mouth to look for mouth sores.\n* Receive light therapy every day while admitted to the hospital on the cancer unit or while admitted to an alternate unit, and continue to receive light therapy in the home setting until they reach 8 days after the start of their chemotherapy cycle.",[186],"Mucositis Oral",[188,189,190],"Photobiomodulation","Mucositis","Oral Mucositis",{"date":192,"type":41},"2026-06-22",{"date":194,"type":23},"2026-08",{"date":196,"type":23},"2027-09",{"name":47,"class":48},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":206,"targetDuration":208,"studyType":160,"phases":4,"briefSummary":209,"conditions":210,"keywords":214,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":226},"100610405","the-hope-biobank-resource-bmt-ctn-2402-hope-100610405","NCT07227155","The HOPE Biobank Resource (BMT CTN 2402 HOPE)","Hematopoietic Cell Transplant and Gene Therapy for Non-Malignant Blood Disorders Biobank Resource (BMT CTN 2402)","HOPE Resource","HCT\u002FGT Inclusion:\n\n1. Patients with a diagnosis of Aplastic Anemia (AA), hemoglobinopathies or bone marrow failure from other causes except for malignant diseases will be eligible for enrollment on this protocol:\n\n   1. AA will be defined as having peripheral blood cytopenias with a hypocellular bone marrow for age and a clinical diagnosis of aplastic anemia as determined by their treating physicians.\n   2. Hemoglobinopathies include sickle cell disease or thalassemia. Patients receiving potentially curative therapy with HCT or GT for hemoglobinopathies will be eligible for this study.\n   3. Individuals with bone marrow failure due to clinical or molecularly diagnosed inherited bone marrow failure, inborn errors of immunity or other cause will be included.\n2. Patients must receive an HCT or GT for management of their underlying disease. Allogeneic transplants including all conditioning regimens, donors, and GVHD prophylaxis regimens are eligible. This study does not define how the transplant or transplant-supportive care will be performed.\n3. Patients or their legal guardian must consent to participate in the CIBMTR \"Protocol for a Research Database for Hematopoietic Cell Transplantation and Marrow Toxic Injuries\" (NCT 1166009) to allow linkage with the longitudinal clinical data collected by CIBMTR.\n4. All ages minorities, sexes and genders are eligible for the study, but participants must weigh at least 10 kilograms (kg) at the time of study enrollment given the volume and number of blood draws required.\n5. All participants or parent\u002Flegal guardian must sign an informed consent for this study. If there are questions regarding a patient's eligibility for the study, contact the Protocol Team for review and discussion by emailing bmtctn2402@emmes.com.\n\nHCT\u002FGT Exclusion\n\n1. Patients with aplastic anemia or hemoglobinopathies who are not pursuing allogeneic HCT or GT.\n2. Active malignancy.\n3. Hematologic malignancy or therapy for a prior hematologic malignancy in the previous five 5 years.\n4. Weight ≤ 10.0 kg at time of study enrollment.\n5. Prior autologous or allogeneic transplant.\n\nRelated Donor Inclusion:\n\n1\\. All related donors for eligible recipients undergoing allogeneic HCT for AA, hemoglobinopathies, or bone marrow failure as defined in the recipient eligibility criteria above are eligible. Note: HCT recipient participants will remain eligible if the related donor declines to participate in the study.\n\nRelated Donor Exclusion:\n\n1\\. Donor weight ≤ 10.0 kg at time of study enrollment",{"count":207,"type":23},375,"5 Years","A prospective, multicenter study that will establish a repository of biospecimens and clinical data from patients undergoing hematopoietic stem cell transplant (HCT) or gene therapy (GT) for treatment of non-malignant blood diseases.",[211,212,213],"Aplastic Anemias","Hemoglobinopathies","Bone Marrow Failure",[215,216,217,218],"Biorepository","Biospecimens","Allogenic Transplant","Gene Therapy","2026-06-12",{"date":164,"type":41},{"date":222,"type":41},"2026-05-15",{"date":224,"type":23},"2031-03-30",{"name":47,"class":48},6,{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":18,"minAge":235,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":24,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":49},"100641698","stimulating-the-aging-brain-using-brain-and-sensory-stimulation-100641698","NCT07650188","Stimulating the Aging Brain Using Brain and Sensory Stimulation","Stimulating the Aging Brain: Noninvasive Brain and Sensory Stimulation Strategies in Aging","StAB","Inclusion Criteria:\n\n* Clinical exam supports diagnosis of PPA and\u002For MCI with no report of difficulty functioning in basic or instrumental activities of daily living.\n* Completed clinical cognitive exam within 6 months of study baseline visit OR neuropsychological research battery within 6 months of study baseline visit.\n\nExclusion Criteria:\n\n* Evidence of dementia at baseline\n* Known history of neoplasm, symptomatic stroke, moderate to severe traumatic brain injury, or other significant neurologic event\n* Age \\\u003C45 years.\n* Evidence of severe psychiatric illness (e.g., bipolar disorder, schizophrenia).\n* Presence of cardiac stimulators or pacemakers\n* Any other implants near the scalp or in the eye\n* Contraindications to MRI or stimulation\n* Pregnancy\n* History of ongoing or unmanaged seizures\n* History of dyslexia or other developmental learning disabilities","45 Years",{"count":237,"type":23},20,[26],"The goal of this project is to investigate whether transcranial electrical stimulation and sensory stimulation affect language outcomes in individuals with primary progressive aphasia (PPA). The main questions it aims to answer are:\n\nDoes transcranial alternating current stimulation (tACS) affect verbal short-term memory (STM) in individuals with PPA? Does a single session of multisensory stimulation affect verbal STM in individuals with PPA? Researchers will compare active tACS to sham tACS (a fake stimulation condition) to see if active tACS improves verbal STM. Researchers will compare pre-multisensory stimulation to post-stimulation performance to see if multisensory stimulation improves verbal STM.\n\nParticipants will:\n\nUndergo EEG, MRI (anatomical and functional) May complete a cognitive exam Undergo tACS over 3 separate sessions Undergo multisensory stimulation Complete language tasks before, during and\u002For after stimulation",[241],"Primary Progressive Aphasia",[243,244],"Transcranial alternating current stimulation","Multisensory stimulation","2026-06-11",{"date":164,"type":41},{"date":248,"type":41},"2026-06-01",{"date":250,"type":23},"2035-05-30",{"name":47,"class":48},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":24,"phases":262,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":49},"100618723","phase-1-fully-human-bispecific-anti-cd20-anti-cd19-car-t-cells-for-patients-with-relapsed-andor-refractory-b-cell-malignancies-100618723","NCT07335328","Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and\u002For Refractory B Cell Malignancies","Phase 1 Study of a Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and\u002For Refractory B Cell Malignancies","General Inclusion Criteria for All Patients\n\n1. Patients must be aged ≥ 18 years and ≤80 years with relapsed or refractory B-cell malignancy.\n2. Absolute CD3 count ≥50 mm\\^3.\n3. Magnetic resonance imaging (MRI) brain and lumbar puncture with cerebral spinal fluid (CSF) analysis by cytology and flow cytometry without evidence of central nervous system (CNS) involvement ONLY in patients with:\n\n   1. A history of CNS involvement OR\n   2. A clinical suspicion at the time of enrollment.\n4. Karnofsky performance score ≥70.\n5. Adequate hepatic function, defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase \\\u003C3 × upper limit of normal (ULN); serum bilirubin \\\u003C2.0 mg\u002FdL, or considered not clinically significant as per the clinical principal investigator's discretion (e.g., Gilbert's or indirect hyperbilirubinemia).\n6. Absolute Neutrophil Count (ANC) ≥1000 with no Granulocyte Colony-Stimulating Factor (G-CSF) within 72 hours or pegylated G-CSF within 14 days.\n7. Platelets ≥50,000 with no transfusion within 72 hours.\n8. Adequate renal function, defined as creatinine clearance ≥50 mL\u002Fmin measured by CKD-EPI 2021 calculator OR 24-hour urine collection.\n9. Left ventricular ejection fraction of ≥45% -- by cardiac echocardiogram (ECHO) or Multigated Acquisition scan (MUGA) -- and adequate pulmonary function as indicated by room air oxygen saturation of ≥92%.\n10. Expected survival \\>12 weeks.\n11. No contraindication to central line access.\n12. Patient has demonstrated compliance with prior therapies.\n13. Meet criteria for regarding fertility and contraception detailed below.\n14. Negative urine or serum pregnancy test in females of childbearing potential at study entry.\n15. Agree to practice birth control during the study.\n16. Able to provide written informed consent.\n\nDisease-Specific Inclusion Criteria\n\n1. Patients must meet at least one of the following criteria within the categories below:\n\n   a. CAR\u002FBispecific antibody exposed:\n\n   i. Relapsed after prior murine CD19 autologous CAR-T cell therapy and be \\>90 days post prior CAR-T cell therapy OR relapsed after bispecific T-cell engaging therapy as a second or later line treatment.\n\n   ii. \\\u003C5% presence of circulating CAR-T cells as measured by flow cytometry in patients with prior CD19 CAR T cell exposure.\n\n   b. CAR naïve patients\n\n   i. For Diffuse Large B-Cell Lymphoma (DLBCL): Progressed after two or more lines of therapy, including at a minimum CD20 antibody and combination cytotoxic chemotherapy regimen (e.g., CHOP, CHP, EPOCH, HyperCVAD) or relapse\u002Fprogression after autologous stem cell transplant\n\n   ii. For Chronic Lymphocytic Leukemia (CLL): Progressed after two or more lines of therapy, including both a covalent Bruton tyrosine kinase (BTK) inhibitor and a BCL2 inhibitor\n\n   iii. For Mantle Cell Lymphoma (MCL): Progressed after two lines of therapy, including CD20 antibody, BTK inhibitor, and one cytotoxic chemotherapy regimen (e.g., bendamustine, cytarabine, CHOP)\n2. Patients must have measurable disease defined as:\n\n   1. For B-cell NHL (DLBCL and MCL): Measurable disease must be documented within 4 weeks of the time of consent, defined as nodal lesions greater than 15 mm in the long axis or extranodal lesions \\>10 mm in long and short axis OR bone marrow involvement that is biopsy-proven for B-cell Non-Hodgkin Lymphoma (NHL)\n   2. For CLL\u002F Small Lymphocytic Lymphoma (SLL): Indication for treatment as defined as any of the following: measurable lymph nodes ≥ 1.5 cm in the greatest transverse diameter and\u002For hepatomegaly or splenomegaly OR bone marrow involvement with ≥10% CLL involvement\n\nExclusion Criteria for All Patients\n\n1. Positive beta human chorionic gonadotropin (hCG) test in female of child-bearing potential.\n2. Confirmed active human immunodeficiency virus (HIV), Hepatitis B or C infection.\n3. History of significant autoimmune disease OR active, uncontrolled autoimmune phenomenon requiring steroid therapy defined as \\>20 mg of prednisone or equivalent daily.\n4. Presence of Grade ≥3 non-hematologic toxicities per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)version 5.0 unless believed to be due to underlying disease.\n5. Concurrent use of investigational therapeutic agents or enrollment on another therapeutic clinical trial at any institution. A minimum of 14 days or 5 half-lives of the drug, whichever is shorter, of washout is required prior to apheresis.\n6. Patients with active CNS involvement by malignancy on MRI or by lumbar puncture:\n\n   a. Patients with prior CNS disease that have been effectively treated will be eligible, provided treatment was \\>4 weeks before enrollment and a remission documented within 8 weeks of planned CAR-T cell infusion by MRI brain and CSF analysis.\n7. Previous recipients of allogeneic hematopoietic stem cell transplantation (AHCT) are excluded if they are \\\u003C100 days post-transplant, have evidence of active graft-versus-host-disease (GVHD) of any grade, or are currently on immunosuppression.\n8. Anti-CD20 antibody treatment within 4 weeks of cell infusion.\n9. Anti-CD19 antibody treatment within 4 weeks of cell infusion.\n10. Cytotoxic chemotherapy other than lymphodepletion within 14 days of the lymphodepletion start date.\n11. Cytotoxic chemotherapy treatment within 14 days or steroid treatment (other than replacement dose steroids) within 7 days prior to apheresis collection for CAR T cells.\n12. Oral chemotherapeutic agents or antibody-directed treatment within 7 days of apheresis:\n\n    a. BTK inhibitors are allowed until 1 day prior to apheresis and can be restarted until 1 day prior to lymphodepletion.\n13. Patients post solid organ transplant who develop high-grade lymphomas or leukemias.\n14. Concurrent active malignancy other than basal or squamous cell carcinomas of the skin (underlying low-grade lymphoma chronic lymphocytic leukemia\u002FFL\u002FMZL is allowable in patients with transformed large cell lymphoma).\n15. Refusal to participate in the long-term follow-up protocol.\n\nSpecial Criteria Regarding Fertility and Contraception Female subjects of reproductive potential (women who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, or have not undergone a sterilization procedure \\[hysterectomy or bilateral oophorectomy\\]) must have a negative serum or urine pregnancy test performed as part of the eligibility criteria.\n\nDue to the high-risk level of this study, while enrolled, all subjects must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). Additionally, if participating in sexual activity that could lead to pregnancy, the study subject must agree to use a reliable and double-barrier methods of contraception during the follow-up period of the protocol.\n\nAcceptable birth control includes a combination of two of the following methods:\n\n* Condoms (male or female) with or without a spermicidal agent.\n* Diaphragm or cervical cap with spermicide.\n* Intrauterine device (IUD).\n* Hormonal-based contraception. Subjects who are not of reproductive potential (women who are premenarche or have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy, tubal ligation, salpingectomy, and\u002For bilateral oophorectomy, or men who have documented azoospermia) are eligible without requiring the use of contraception.","80 Years",{"count":261,"type":23},24,[263],"PHASE1","This is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.",[266],"B-cell Non Hodgkin Lymphoma",[268,269,270],"CAR-T","Chimeric antigen receptor T-cell therapy","CAR Therapy","2026-06-09",{"date":245,"type":41},{"date":274,"type":23},"2026-09-01",{"date":276,"type":23},"2031-05-01",{"name":47,"class":48},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":24,"phases":288,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":297,"leadSponsor":299,"locationsCount":49},"100643602","phase-2-cancer-lipidome-adaptation-and-resculping-through-omega-3-pufas-in-breast-tumors-100643602","NCT07643428","Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors","Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors (CLARA)","CLARA","Inclusion Criteria:\n\n* Patient must be ≥18 years of age.\n* Breast tumor ≥1 cm.\n* Not currently taking dietary supplements containing fish oil or omega-3 PUFAs. A diet containing fish meat is permitted.\n* Unilateral and\u002For bilateral diagnostic breast mammogram and\u002For ultrasound within 60 days of enrollment. If breast MRI is done per treating physician's discretion, at least one breast imaging modality should be within 60 days of enrollment.\n* Pathologically proven diagnosis of invasive breast cancer, clinical stage I-III (cT1c-T4, N0-N3, M0).\n* Concurrent (neoadjuvant) systemic anti-cancer therapy is planned, including but not limited to endocrine therapy, chemotherapy, anti-HER2 therapy, and immunotherapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n* Bilateral breast cancer and\u002For multifocal, multicentric disease is allowed.\n* Appropriate pretreatment evaluations for protocol entry, including no clinical evidence for distant metastases, based upon the following minimum diagnostic workup: history\u002Fphysical examination, including breast exam (inspection and palpation of the breasts), within 30 days prior to study entry.\n* Patients with a prior history of breast cancer will be considered eligible.\n* Surgical candidacy as determined by the treating physician.\n* Patient must provide study-specific informed consent prior to study entry or have a legally authorized representative provide consent.\n\nExclusion Criteria:\n\n* American Joint Committee on Cancer (AJCC) clinical M1 breast cancer (i.e., with distant metastasis).\n* Purely noninvasive breast cancer (i.e., ductal carcinoma in situ, lobular carcinoma in situ).\n* Medical, psychiatric, or other condition that would prevent the patient from receiving the protocol treatment or providing informed consent.",{"count":287,"type":23},35,[132],"This is a single-arm Phase 2 interventional treatment study to investigate changes in tissue lipidomes with omega-3 polyunsaturated fatty acids (PUFA) supplementation and correlations with pathological response in patients with early-stage breast cancer. Patients will be treated with a dietary supplement enriched with omega-3 PUFA (O3Supp) for 4 to 28 weeks prior to surgical resection of a breast tumor(s). Concurrent standard-of-care neoadjuvant treatment with clinically indicated systemic agents (such as chemotherapy, endocrine therapy, anti-HER2 therapy, immunotherapy) is allowed.",[291],"Breast Cancer",[293],"omega-3 Polyunsaturated fatty acids","2026-06-07",{"date":245,"type":41},{"date":274,"type":23},{"date":298,"type":23},"2028-06-01",{"name":47,"class":48},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":24,"phases":310,"briefSummary":311,"conditions":312,"keywords":316,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":49},"100638769","amnioinfusion-for-chorioamnionitis-targeting-neonatal-brain-injury-biomarkers-100638769","NCT07610642","Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers","The AMNIO-BRAIN Trial: A Randomized Trial of Amnioinfusion for Chorioamnionitis Targeting Neonatal Brain Injury Biomarkers","AMNIO-BRAIN","Inclusion Criteria:\n\n* Maternal age ≥18 years\n* Singleton gestation\n* Gestational age ≥36 weeks\n* Labor at time of enrollment\n* Clinical chorioamnionitis or intra-amniotic infection defined according to ACOG criteria, including: Maternal temperature ≥38.0°C At least one associated clinical finding, including:\n* 1\\. Maternal leukocytosis\n* 2\\. Purulent cervical drainage\n* 3\\. Fetal tachycardia\n* Cervical dilation sufficient for intrauterine pressure catheter placement\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Multifetal gestation\n* Known major fetal anomaly\n* Contraindication to vaginal delivery\n* Placenta previa\n* Category III fetal heart tracing requiring immediate delivery\n* Non-English-speaking",{"count":309,"type":23},80,[26],"The AMNIO-BRAIN Trial is a research study looking at whether a simple treatment during labor can help protect a baby's brain.\n\nSome newborns develop a condition called hypoxic-ischemic encephalopathy (HIE), which happens when the brain does not get enough oxygen or blood flow. This can lead to serious health problems, including developmental delays and lifelong disabilities. While there is a cooling treatment after birth that can help, it starts only after delivery and may come too late to prevent the earliest stages of injury.\n\nResearch suggests that some brain injury may actually begin during labor, especially when there is an infection in the uterus called chorioamnionitis. This infection can cause inflammation and fever in the mother, which may increase stress on the baby and affect the baby's brain.\n\nThis study is testing whether a commonly used labor procedure called amnioinfusion can help. Amnioinfusion involves placing fluid similar to your biologic amniotic fluid into the uterus during labor. It is already used safely in many deliveries for other reasons. In prior research, this treatment slightly lowered the temperature inside the uterus and improved signs that the baby was no longer under stress.\n\nIn this study, 80 pregnant subjects with chorioamnionitis will be randomly assigned to receive amnioinfusion during labor or receive standard care without amnioinfusion. All patients will continue to receive normal treatment for infection.\n\nAfter delivery, researchers will collect a small sample of blood from the umbilical cord. This blood will be tested for markers that can show whether the baby may have experienced stress or injury to the brain.",[313,314,315],"Chorioamnionitis Affecting Fetus or Newborn","Amnioinfusion","Neonatal Brain Injury",[314,317,318,319,320,321,322,323],"Neonatal morbidity","Maternal morbidity","Umbilical cord gas","Healthcare Utilization","Neonatal hypoxic brain injury","Chorioamnionitis","Neonatal brain biomarkers","2026-05-27",{"date":326,"type":41},"2026-05-29",{"date":328,"type":23},"2026-07-01",{"date":330,"type":23},"2027-12",{"name":47,"class":48},{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":338,"minAge":19,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":24,"phases":341,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":352},"100268501","gastroschisis-outcomes-of-delivery-good-study-100268501","NCT02774746","Gastroschisis Outcomes of Delivery (GOOD) Study","Inclusion criteria:\n\nTo be eligible for study inclusion, subjects are required to meet the following criteria:\n\n1. Speak English or Spanish\n2. Age of ≥18 years old\n3. Have a diagnosis of an isolated fetal gastroschisis confirmed via sonogram at ≤33 weeks gestation\n4. Have a singleton pregnancy\n5. Capable of providing written informed consent for study participation\n6. Established Estimated Date of Confinement (EDC) prior to 22 0\u002F7 weeks GA by last menstrual period (LMP) with ultrasound confirmation or ultrasound dating when LMP is unknown.\n\nExclusion criteria:\n\nSubjects will be excluded from enrollment for any of the following criteria\n\n1. Fetal anomaly unrelated to gastroschisis, such as a chromosomal abnormality or another congenital structural abnormality (if known; no additional testing required for research participation)\n2. Severe intrauterine growth restriction \u002F fetal growth restriction (defined as growth below the 5th percentile for gestational age)\n3. Maternal history of previous stillbirth (intrauterine fetal demise)\n4. Maternal history of spontaneous preterm (\\\u003C36 weeks) delivery\n5. Maternal cervical length \\\u003C 25 mm prior to 24 weeks of gestation if documented\n6. Maternal hypertension\n7. Maternal insulin-dependent diabetes\n8. Prenatal care initiated after 24 weeks of gestation\n9. An active case of COVID-19 (confirmed by a positive test for COVID-19) that is not recovered (confirmed by a negative test for COVID-19) by the date of randomization\n10. Unstable pregnancy defined as meeting any of the following criteria\n\n    1. Abnormal amniotic fluid volume defined as oligohydramnios or polyhydramnios where the maximal vertical pocket (MVP) is \\\u003C 2 cm or \\> 8 cm in the third trimester, respectively\n    2. Umbilical artery Dopplers with S\u002FD ratio or resistive index (RI) \\> 97th percentile for age with or without absent or reversed end diastolic flow\n    3. Non-stress test (NST) or biophysical profile (BPP) deemed non-reassuring by treating clinician\n11. Concurrent enrollment in another study that requires either a treatment or intervention which would either alter the delivery plan or potentially influence the maternal, fetal, and neonatal outcomes of this study\n12. Traditional surrogacy, gestational surrogacy, gestational carrier, or gestational surrogate\n13. Incapable of providing informed consent\n14. Are not their own legally authorized representative.","FEMALE",{"count":340,"type":23},300,[26],"The objective of this study is to investigate the hypothesis that delivery at 35 0\u002F7- 35 6\u002F7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0\u002F7 - 38 6\u002F7 weeks. To test this hypothesis, we will complete a randomized, prospective, multi-institutional trial across NAFTNet-affiliated institutions. Patients may be enrolled in the study any time prior to 33 weeks, but will be randomized at 33 weeks to delivery at 35 weeks or observation with a goal of 38 weeks. The primary composite outcome will include stillbirth, neonatal death prior to discharge, respiratory morbidity, and need for parenteral nutrition at 30 days.",[344],"Gastroschisis","2026-05-22",{"date":324,"type":41},{"date":348,"type":41},"2018-02-23",{"date":350,"type":23},"2029-03-31",{"name":47,"class":48},38,{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":18,"minAge":359,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":362,"conditions":363,"keywords":365,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":49},"100568492","defining-mechanisms-of-surgical-site-infection-after-oral-cancer-surgery-100568492","NCT06681935","Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery","Inclusion Criteria:\n\n1. Provide signed and dated informed consent form. Subjects must have the capacity to consent for themselves.\n2. Willing to comply with all study procedures and be available for the duration of the study.\n3. Aged 21 years or older.\n4. Planned to undergo standard of care oral cavity reconstruction surgery with use of ampicillin\u002Fsulbactam as the prophylactic antibiotic agent administered.\n5. Oral cavity reconstruction surgery will be defined as any surgical procedure which includes a planned connection from the oral cavity to the neck soft tissues which is repaired with a free or regional tissue flap.\n6. History of oral or oropharyngeal cancer.\n\nExclusion Criteria:\n\n1. Allergy to ampicillin\u002Fsulbactam.\n2. Vulnerable populations including pregnant women and prisoners.","21 Years",{"count":361,"type":23},40,"The study design is an observational cohort study of patients undergoing standard of care oral cavity reconstruction. An observational study is required to prospectively evaluate microbial and antibiotic mechanisms underlying surgical site infection after oral cavity reconstruction.",[364],"Oral Cancer",[366,367],"Surgical Site Infection","Oral Cavity Reconstruction","2026-05-19",{"date":345,"type":41},{"date":371,"type":41},"2025-04-29",{"date":373,"type":23},"2026-07-15",{"name":47,"class":48},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":24,"phases":385,"briefSummary":386,"conditions":387,"keywords":389,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":49},"100491107","phase-1-investigation-of-profile-related-evidence-determining-individualized-cancer-therapy-for-patients-with-aggressive-malignancies-and-poor-prognoses-100491107","NCT05674825","Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses","An Open-label, Navigational Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses","MCW I-PREDICT","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Patient with aggressive solid malignancy must meet at least one of the following:\n\n   1. Malignancy with ≥30% two-year cancer-associated mortality as estimated by the treating oncologist and one of the study investigators and\u002For, where appropriate, according to accepted data sets in the field (e.g., NCDB). Diseases include but are not limited to: ampullary carcinoma, appendiceal cancer, colorectal cancer (CRC), extrahepatic cholangiocarcinoma (EHCC), esophageal adenocarcinoma, gallbladder cancer (GBCA) gastric adenocarcinoma, head and neck cancer, hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (IHCC), melanoma, non-KIT gastrointestinal stromal tumor (GIST), non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic ductal adenocarcinoma (PDAC), sarcoma (high-grade), small bowel adenocarcinoma (including duodenal), triple-negative breast cancer (TNBC), urothelial cancer\n   2. Refused standard therapies, OR\n   3. Cancer of unknown primary or a rare tumor (i.e., fewer than 4 cases per 100,000 per year) with no approved therapies.\n3. Patient with aggressive solid malignancy irrespective of two-year mortality who, in the opinion of the investigator, has no treatment option expected to yield significant clinical benefit.\n4. Patient must have at least one of the following for a diagnosis\u002Fdisease status:\n\n   1. Unresectable disease, as determined by a disease-appropriate multidisciplinary tumor board.\n   2. Medically unfit for surgical resection but with an expected survival of \\> three months.\n   3. Localized disease and are eligible for neoadjuvant treatment.\n   4. Metastatic disease.\n   5. Disease where no conventional therapy leads to a survival benefit \\> six months in the respective cohort and line of therapy for which the patient is otherwise eligible.\n5. Patient is either:\n\n   1. Treatment naïve for their newly diagnosed malignancy (for enrollment to Groups 1 or 2), or\n   2. Status post one or more systemic therapy regimens, whether matched or unmatched (for enrollment to Group 3). Note: There are no limitations on the number of prior local therapies.\n6. Patient must have measurable disease for malignancy: defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, positron emission tomography (PET) -CT, MRI, or calipers by clinical exam.\n7. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n8. New York Heart Association (NYHA) Functional Classification I-II\n9. Adequate organ and marrow function as defined below:\n\n   1. Absolute neutrophil count ≥ 1.0 x 109\u002FL\n   2. Platelet count ≥ 75 x 109\u002FL\n   3. Total bilirubin ≤ 2.0 x institution's upper limit of normal (ULN)\n   4. Patients without underlying liver disease\n\n      • alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 3 x institutional ULN\n   5. Serum creatinine ≤ 2.0 x institution's ULN or 24-hour creatinine clearance ≥ 30 ml\u002Fmin\n10. At the time of treatment, patient should be off other anti-tumor agents for at least five half-lives of the agent or two weeks from the last day of treatment, whichever is shorter to enroll in Group 3. Patient must not have been treated with anti-tumor agents to enroll in Group 1 or Group 2. Patient must be off prior antibody therapy for at least three half-lives before starting treatment.\n11. Able to swallow and retain oral medication, if needed.\n12. If actionable or appropriate molecular profiling has not already been performed, patient must have or provide evaluable tissue and\u002For blood for molecular profiling. This could be obtained during the standard of care tumor diagnosis or tumor staging evaluation. Tissue and\u002For blood is to be procured based on clinical discretion and discussion with the patient.\n13. Pregnancy It is not known what effects matched therapy has on human pregnancy or development of the embryo or fetus. Therefore, female subjects participating in this study should avoid becoming pregnant, and male subjects should avoid impregnating a female partner. Non-sterilized female subjects of reproductive age and male subjects should use effective methods of contraception through defined periods during and after study treatment as specified below.\n\n    Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n    * Not a female of childbearing potential (FCBP), defined as all female patients that were not in post-menopause for at least one year or are surgically sterile, OR\n    * An FCBP must have a negative serum pregnancy test and agree to use at least one form of pregnancy prevention during the study for at least one month after treatment discontinuation unless otherwise noted by the agent(s) USPI or IB, which the FCBP must follow.\n\n    Male participants: A male participant, even if surgically sterilized (i.e., status post-vasectomy), must use a form of barrier pregnancy prevention approved by the investigator or treating physician during the study and for at least one month after treatment discontinuation and refrain from donating sperm during this period unless otherwise noted by the agent(s) U.S. Prescribing Information (USPI) or investigator's brochure (IB), which the male participant must follow.\n14. Ability to understand a written informed consent document, and the willingness to sign it.\n15. Patients presented at Molecular Tumor Board (MTB) up to two weeks prior to signing consent are eligible to be treated on study based on the MTB recommendations and do not need to be represented at MTB prior to starting therapy on trial (unless six months elapsed between consent and start of study treatment).\n\nExclusion Criteria:\n\nA potential study subject who meets any of the following exclusion criteria is ineligible to participate in the study.\n\n1. Two oncologists disagree on prognosis or resectability.\n2. Severe or uncontrolled medical disorder that would, in the investigator's opinion, confound study analyses of treatment response (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric illness\u002Fsocial situations that would limit compliance with study requirements).\n3. Is pregnant or breastfeeding or any patient with childbearing potential not using adequate pregnancy prevention.\n4. Whole brain radiation or stereotactic radiotherapy to CNS metastases within 14 days prior to start of study treatment.",{"count":384,"type":23},400,[263,132],"This is a prospective, open-label navigational investigation designed to evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with aggressive malignancies. This is a non-randomized, histology-agnostic trial. Although there will be a case mix of histologies, the investigators now know that individual histologies are composed of a heterogeneous mix of molecular alterations. It is not clear whether one case mix is better or worse than another. Thus, the investigators are testing a strategy of molecular matching that may apply across different cancers.",[388],"Cancer",[390,391,392,393],"metastatic disease","unresectable disease","advanced malignancies","molecular profile",{"date":345,"type":41},{"date":396,"type":41},"2022-12-21",{"date":398,"type":23},"2031-01",{"name":47,"class":48},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":259,"enrollmentInfo":407,"targetDuration":4,"studyType":24,"phases":409,"briefSummary":410,"conditions":411,"keywords":413,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":420,"locationsCount":4},"100514289","phase-1-phase-i-trial-of-bcma-tgf-beta-car-t-cells-in-relapsed-refractory-myeloma-100514289","NCT05976555","Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma","Phase I Study of BCMA-TGF-BETA Insensitive Armored CAR T Cells in Patients With Relapsed and\u002For Refractory Multiple Myeloma","Inclusion Criteria:\n\n1. Patients must be aged ≥18 years to 80 years old.\n2. Patients must have received three prior lines of therapies, including proteasome inhibitor, immunomodulator and a cluster of differentiation (CD) 38 monoclonal antibody:\n\n   • International Myeloma Working Group (IMWG) criteria defines refractory disease as disease progression on or within 60 days of receiving therapy.\n3. Patients must have measurable disease, including at least one or more of the following criteria:\n\n   1. Serum M-protein ≥0.5 g\u002Fdl;\n   2. Urine M-protein ≥200 mg\u002F24 hrs;\n   3. Involved serum light chain ≥100 mg\u002FL with abnormal light chain ratio;\n4. Absolute CD 3 count ≥50 mm\\^3.\n5. Karnofsky performance score ≥70.\n6. Adequate hepatic function, defined as:\n\n   1. aspartate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase \\\u003C3x upper limit of normal (ULN);\n   2. Serum bilirubin \\\u003C2.0 mg\u002FdL except for patients with Gilbert's syndrome, who must have serum bilirubin of \\\u003C3 mg\u002FdL.\n7. Absolute neutrophil count (ANC) ≥1,000 with no Granulocyte colony-stimulating factor (G-CSF) within 72 hours or pegylated G-CSF within 10 days.\n8. Platelets ≥50,000\u002FµL with no transfusion within 72 hours of eligibility testing.\n9. Adequate renal function, defined as creatinine clearance ≥50 mL\u002Fmin calculated using the Cockroft-Gault formula.\n10. Able to provide written informed consent.\n11. Agree to practice birth control during the study.\n12. Adequate cardiac function as indicated by New York Heart Association (NYHA) classification I or II AND left ventricular ejection fraction of ≥45% (by cardiac echocardiogram (ECHO) or multigated acquisition (MUGA)) and adequate pulmonary function as indicated by room air oxygen saturation of ≥90%.\n13. Expected survival \\>12 weeks.\n14. Negative urine or serum pregnancy test in females of childbearing potential at study entry.\n15. Meet criteria for regarding fertility and contraception detailed below.\n16. No contraindication to central line access.\n\nPhase I Dose-Expansion Cohort A: BCMA Naïve The inclusion criteria for dose-expansion Cohort A are the same as that listed above but are limited to BCMA naïve patients.\n\nPhase I Dose-Expansion Cohort B: BCMA Exposed The inclusion criteria for dose expansion Cohort B are the same as that above but require prior exposure to BCMA directed therapies (e.g., CAR-BCMA, bispecific T\u002F Natural Killer (NK) cell engagers of BCMA).\n\nPatients with prior antibody drug conjugate, bispecific T and NK cell engager and prior gene-modified cellular immune therapy against BCMA are allowed. Patients must be \\> 3 months out from therapy and must have achieved stable disease or better with prior BCMA-directed therapy.\n\nExclusion Criteria:\n\n1. Positive beta- Human chorionic gonadotropin (HCG) in female of child-bearing potential defined as per the Schedule of Events table.\n2. Confirmed active human immunodeficiency virus (HIV), Hepatitis B or C infection.\n3. History of significant autoimmune disease OR active, uncontrolled autoimmune phenomenon requiring steroid therapy defined as \\>20 mg of prednisone or equivalent daily.\n4. Presence of ≥ Grade 3 non-hematologic toxicities as per CTCAE version 5.0 from any previous treatment unless it is felt to be due to underlying disease.\n5. Concurrent use of investigational therapeutic agents or enrollment on another therapeutic clinical trial at any institution. Minimum of 14 days or 5 half-lives of the drug (whichever is shorter) washout prior to apheresis.\n6. Refusal to participate in the long-term follow-up protocol.\n7. Patients with active central nervous system (CNS) involvement by malignancy on MRI or by lumbar puncture.\n\n   a. Patients with prior CNS disease that has been effectively treated will be eligible providing last treatment was ≥2 weeks before apheresis and a remission documented within 4 weeks of planned CAR T-cell infusion by MRI brain and CSF analysis.\n8. Previous recipients of allogeneic hematopoietic stem cell transplantation (AHCT) are excluded if they are \\\u003C6 months post-transplant, have evidence of active graft-versus-host-disease (GVHD) of any grade, or are currently on immunosuppression.\n9. Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, and AL amyloidosis.\n10. Prior treatment with gene therapy or any gene modified cellular therapy (only permitted in cohort B for the dose expansion phase).\n11. Prior BCMA-directed therapy (only permitted in cohort B for the dose expansion phase).\n12. Cytotoxic chemotherapy, oral chemotherapeutic agents, or antibody-directed treatment within 14 days of apheresis or after apheresis.\n\n    1. Corticosteroids are allowable up until 7 days prior to apheresis and after apheresis for disease control up until the day prior to cell infusion (Day -1).\n    2. Radiation is allowed to a single symptomatic site.\n13. Patients post solid organ transplant who develop high grade lymphomas or leukemias.\n14. Concurrent active malignancy other than basal or squamous cell carcinomas of the skin.\n15. Active bacterial, viral, or fungal infection requiring systemic treatment.\n16. Patients who have received major surgery 1 week prior to leukapheresis and 3 weeks prior to lymphodepletion.\n17. Active malignancy that required therapy in the last 2 years except successfully treated non metastatic basal or squamous cell carcinoma, or prostate carcinoma that does not require therapy. Other similar conditions may be discussed with and permitted by the medical monitor.\n\nSpecial Criteria Regarding Fertility and Contraception\n\nFemale subjects of reproductive potential (women who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, or have not undergone a sterilization procedure \\[hysterectomy or bilateral oophorectomy\\]) must have a negative serum or urine pregnancy test performed as part of eligibility criteria. Lactating women are eligible for this study but will be asked to not provide breast milk to their child from Day -4 through Day +90 after CAR T-cell therapy.\n\nDue to the high-risk level of this study, while enrolled, all subjects must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). Additionally, if participating in sexual activity that could lead to pregnancy, the study subject must agree to use reliable and double barrier methods of contraception during the follow-up period of the protocol.\n\nAcceptable birth control includes a combination of two of the following methods:\n\n* Condoms (male or female) with or without a spermicidal agent.\n* Diaphragm or cervical cap with spermicide.\n* Intrauterine device (IUD).\n* Hormonal-based contraception. Subjects who are not of reproductive potential (women who are premenarche or have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy, tubal ligation, salpingectomy, and\u002For bilateral oophorectomy or men who have documented azoospermia) are eligible without requiring the use of contraception.",{"count":408,"type":23},30,[263],"This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and efficacy of interleukin-7(IL-7) \u002F interleukin-15 (IL-15) manufactured CAR T cells in adult patients with relapsed and\u002For refractory myeloma that have failed prior therapies.",[412],"Multiple Myeloma",[268,269,270],"2026-05-18",{"date":416,"type":41},"2026-05-20",{"date":328,"type":23},{"date":419,"type":23},"2029-05",{"name":47,"class":48},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":24,"phases":431,"briefSummary":432,"conditions":433,"keywords":445,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":451,"leadSponsor":453,"locationsCount":49},"100614048","amnioinfusions-protective-effects-on-respiratory-and-longitudinal-pediatric-outcomes-after-intrapartum-thick-meconium-exposure-100614048","NCT07274527","Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Thick Meconium Exposure","The PEARL Trial: A Randomized Trial of Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Thick Meconium Exposure","PEARL","Inclusion Criteria:\n\n* Maternal age greater than or equal to 18 years old\n* Singleton pregnancy\n* Gestational age of greater than or equal to 36 weeks 0 days gestation\n* Cephalic presentation\n* Cercial dilation between 2-10 centimeters\n* Meconium\n\nExclusion Criteria:\n\n* Major fetal anomaly\n* Multiple gestation\n* Eunice Kennedy Shrive National Institute of Child Health and Human Developmet (NICHD) Category III fetal heart tracing\n* Contraindication to internal monitors\n* Prelabor premature ruptuore of membranes before 36 weeks 0 days gestation, - Inability to consent",{"count":430,"type":23},320,[26],"Thick meconium in the amniotic fluid occurs in about one out of seven pregnancies and increases the chance that a newborn may have breathing problems after birth. These problems can include the need for oxygen, breathing support, admission to the neonatal intensive care unit (NICU), or, in severe cases, meconium aspiration syndrome or persistent pulmonary hypertension.\n\nAlthough amnioinfusion or placing sterile fluid into the uterus during labor was previously studied as a way to reduce these complications, earlier research had major limitations. Past studies included all types of meconium, used different fluid types and temperatures, had inconsistent protocols, and did not measure biomarkers of inflammation or look at long-term outcomes. As a result, it is still unclear whether a modern, standardized approach to amnioinfusion can meaningfully improve newborn health when the meconium is truly thick.\n\nThe PEARL Trial is a randomized clinical trial designed to answer this question. The study will enroll pregnant individuals at or beyond 36 weeks of gestation who develop thick meconium-stained amniotic fluid, confirmed using a simple, objective measurement (\"meconium-crit\"). Participants will be randomly assigned to receive either:\n\nWarm lactated Ringer's (LR) amnioinfusion through an intrauterine pressure catheter (IUPC), following a standardized protocol, or standard care without amnioinfusion.\n\nThe main goal is to determine whether warm LR amnioinfusion reduces short-term breathing problems in newborns. The study also collects umbilical cord blood at birth to evaluate markers of inflammation and potential brain injury, which may help explain why some infants develop complications. Families will also be contacted when their child is 12 months old to complete a developmental questionnaire that is widely used in pediatric practice.\n\nBy using a clear definition of thick meconium, a warm LR infusion protocol, fidelity checklists, and long-term follow-up, this trial aims to provide high-quality evidence to guide care in labor and delivery units nationwide.",[434,435,436,437,438,315,439,440,441,442,443,314,444],"Neonatal Respiratory Distress Related Conditions","Meconium","Perinatal Morbidity","Neonatal Acidosis","Cord Blood","Maternal Morbidity","Mechanical Ventilation","CPAP","Surfactant","Perinatal Death","NICU Admission",[314,435,317,446,439,447,448,320],"Developmental Screening","Neonatal respiratory morbidity","Umbilical cord gas and biomarkers",{"date":368,"type":41},{"date":222,"type":41},{"date":452,"type":23},"2030-04-15",{"name":47,"class":48},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":17,"sex":18,"minAge":462,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":24,"phases":465,"briefSummary":466,"conditions":467,"keywords":469,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":477,"locationsCount":478},"100607707","self-sampling-to-optimize-anal-lesion-outcomes-100607707","NCT07192055","Self-sampling to Optimize Anal Lesion Outcomes","Self-sampling to Optimize Anal Lesion Outcomes (SOLO)","SOLO","A potential study subject who meets all of the following inclusion criteria is eligible to participate in the study. Note that these criteria apply regardless of HPV vaccination status or disability status.\n\nInclusion Criteria:\n\n1. Age ≥ 35 years for those who are HIV-positive or ≥ 45 years for those who are HIV-negative.\n2. Must be either:\n\n   1. A cisgender or transgender sexual minority man, or\n   2. A transgender woman who has sex with men.\n3. Resides in Chicago, Houston, or Milwaukee metropolitan area.\n4. Is willing to attend a study clinic.\n5. Speak and understand either English or Spanish\n6. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\nA potential study subject who meets any of the following exclusion criteria is ineligible to participate in the study.\n\n1. Was a participant in the PAC Self-Swab Study in Milwaukee.\n2. Currently on anticoagulants, with the exception of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs), e.g., ibuprofen, naproxen.\n3. Diagnosed with hemophilia, cirrhosis with bleeding varices, or thrombocytopenia.\n4. Presence of any contraindicating severe disease or condition, e.g., anal stenosis.\n5. Plans to move within 12 months after enrollment.","35 Years",{"count":464,"type":23},572,[26],"The purpose of this research study is to find ways to increase anal cancer screening among people at increased risk for anal cancer. This study will try to find out if persons will do an intervention (self-sampling of the anal canal) and if it affects cytology and high-resolution anoscopy (HRA) appointment attendance. Secondarily, the study will assess if a person who gets their choice of either self-sampling or healthcare provider sampling affects clinic attendance.",[468],"Anal Cancer",[470,471],"anal cancer","human papillomavirus",{"date":473,"type":41},"2026-05-12",{"date":475,"type":41},"2025-11-18",{"date":350,"type":23},{"name":47,"class":48},3,{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":486,"maxAge":487,"enrollmentInfo":488,"targetDuration":4,"studyType":24,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":49},"100500332","mcw-alphabeta-t-cell-and-b-cell-depletion-with-targeted-atg-dosing-100500332","NCT05794880","MCW Alpha\u002FBeta T-Cell and B-Cell Depletion With Targeted ATG Dosing","Matched Unrelated Donor and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha\u002FBeta T-Cell and B-Cell Depletion for Patients With Hematologic Malignancies With Targeted ATG Dosing Pilot Study, IDE 13641","Inclusion Criteria:\n\n1. Patient age \\\u003C 25 years. Both genders and all races eligible.\n2. Disease eligibility\n\n   * Acute myeloid leukemia, primary or secondary - Disease status: MRD negative (flow MRD ≤ 0.1%)\n   * Myelodysplasia\n   * Acute lymphoblastic leukemia - Disease status: MRD negative\n   * Chronic myelogenous leukemia - Disease status: chronic phase, accelerated phase or blast crisis now in second chronic phase\n   * Mixed lineage or biphenotypic acute leukemia- Disease status: MRD negative\n   * Lymphoblastic lymphoma - Disease status: in remission\n   * Burkitt's lymphoma\u002Fleukemia - Disease status: in remission\n   * Lymphoma after relapse - Disease status: in remission\n   * Other malignant hematologic diseases in remission (to be approved by PI)\n3. Karnofsky Performance Status ≥ 60% for patients 16 years and older and Lansky Play Score ≥ 60 for patients under 16 years of age (Appendix 1)\n4. Evaluation of organ status as per MCW BMT SOP\n5. Infectious disease criteria: No active untreated infection. Patients with possible fungal infections must have had at least 2 weeks of appropriate anti-fungal antibiotics and be asymptomatic.\n6. Signed consent by parent\u002Fguardian or able to give consent if ≥18 years.\n7. Negative pregnancy test for patients capable of childbearing potential\n8. Sexually active patients capable of child-bearing potential must agree to use adequate contraception (diaphragm, birth control pills, injections, intrauterine device \\[IUD\\], surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration of treatment. Sexually active men must agree to use barrier contraceptive for the duration of treatment.\n\nDonor Eligibility:\n\n1. Unrelated donor meets National Marrow Donor Program criteria for donation\n2. Infectious disease testing\n3. MCW BMT procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases.\n4. Only Peripheral blood stem cells will be used for stem cell source on this study therefore donor must be willing to undergo G-CSF mobilization and stem cell apheresis. Donor matching. High resolution typing at all loci to be performed.\n5. Unrelated Donor:\n\n   a. HLA typing of at least 10 alleles is required. Donor must be matched at 9\u002F10 or 10\u002F10 alleles (HLA A, B, C, DRB1, DQB1).Donor and collection center willing to undergo mobilization and apheresis\n6. Haploidentical Related Donor:\n\n   1. Haploidentical parent or other related donor: Minimum match level full haploidentical (at least 5\u002F10; HLA A, B, C, DRB1, DQB1 alleles), but use of haploidentical donors with extra matches (e.g. 6, 7, or 8\u002F10) encouraged.\n\nExclusion Criteria:\n\n1. Patients who do not meet disease, organ, or infectious criteria.\n2. No suitable donor\n3. Pregnant or lactating patients are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants\n4. Receiving concomitant chemotherapy, radiation therapy; immunotherapy or other anti-cancer therapy for treatment of disease other than is specified in the protocol. Maintenance or other post-HCT therapy can be considered after discussion with the study PI.\n5. Participating in a concomitant Phase 1 or 2 study involving treatment of disease\n6. Active malignancy other than eligible disease specified in the protocol. Patients with prior malignancy can be eligible as long as at least 1 year post treatment for that malignancy.","0 Years","25 Years",{"count":361,"type":23},[26],"This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha\u002Fbeta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival",[492,493,494,495,496,497,498,499,500,501,502,503,504],"Leukemia","Acute Myeloid Leukemia in Remission","Myelodysplasia","Acute Lymphoblastic Leukemia in Remission","Chronic Myelogenous Leukemia - Chronic Phase","Chronic Myelogenous Leukemia, Accelerated Phase","Chronic Myelogenous Leukemia With Crisis of Blast Cells","Biphenotypic Acute Leukemia","Lymphoblastic Lymphoma","Burkitt Lymphoma","Burkitt Leukemia","Lymphoma After Relapse","Other Malignant Hematologic Diseases in Remission","2026-05-08",{"date":507,"type":41},"2026-05-13",{"date":509,"type":41},"2023-05-01",{"date":511,"type":23},"2032-05",{"name":47,"class":48},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":520,"enrollmentInfo":521,"targetDuration":4,"studyType":24,"phases":522,"briefSummary":523,"conditions":524,"keywords":528,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":49},"100441061","a-study-to-measure-the-effect-of-brain-stimulation-on-hand-strength-and-function-in-patients-with-brain-tumors-100441061","NCT05023434","A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors","The Effect of Intraoperative Cortical Stimulation on Hand Strength and Function During Awake Craniotomies","AWAKE CRANIOTOMY COHORT\n\nInclusion Criteria:\n\n1. Age 18 - 75\n2. Ability to understand a written informed consent document, and the willingness to sign it\n3. Radiographic evidence of tumor on MRI (i.e. non-enhancing) invading primary motor cortex in the non-dominant hemisphere.\n4. Karnofsky performance status (KPS) ≥ 70\n5. Normal or near normal motor strength (i.e., at least 3\u002F5 in relevant areas)\n6. Normal or near normal speech (Can consistently name at least 4\u002F5 cards)\n7. Free of other illness, in the judgment of the investigator, that may shorten life expectancy\n8. Willing and able to participate in all aspects of the study\n\nExclusion Criteria:\n\n1. Presence of other malignancy not in remission\n2. Evidence of bi-hemispheric or widespread tumor involvement\n3. Medically high-risk surgical candidate\n4. History of recent scalp or systemic infection\n5. Presence of other implants or foreign bodies in the head\n6. Inability to receive an MRI for any reason\n7. Inability to receive cortical stimulation for any reason\n8. Presence of implanted cardiac device (such as a pacemaker or defibrillator)","75 Years",{"count":237,"type":23},[26],"The neurosurgical standard of care for treating a patient with a tumor invading hand primary motor cortex (M1) includes performing a craniotomy with intraoperative direct electrical stimulation (DES) mapping and to resect as much tumor as possible without a resultant permanent neurological deficit. However, the subjective nature of current intraoperative hand motor assessments do not offer a comprehensive understanding of how hand strength and function may be impacted by resection. Additionally, there is a paucity of data to inform how altering DES parameters may effect motor mapping. Here, the investigators seek to demonstrate a feasible, standardized protocol to quantitatively assess hand strength and function and systematically assess several stimulation parameters to improve intraoperative measurements and better understand how cortical stimulation interacts with underlying neural function.",[525,526,527],"Brain Tumor","Brain Cancer","Motor Cortex; Lesion",[529,530,531,532,533,534,535,536,537,538],"Brain Stimulation","Cortex Stimulation","Hand Motor Cortex","Primary Motor Cortex","M1","Resection","Surgery","Healthy Volunteers","Hand Strength","Hand Function","2026-05-05",{"date":71,"type":41},{"date":542,"type":41},"2023-04-17",{"date":544,"type":23},"2028-12-01",{"name":47,"class":48},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":49},"100235534","intra--and-inter-fraction-changes-in-radiation-therapy-100235534","NCT02344121","Intra- and Inter-fraction Changes in Radiation Therapy","Inclusion Criteria:\n\n°Completed radiation therapy\n\nExclusion Criteria:\n\n°Subjects who refuse voluntary participation",{"count":553,"type":23},500,"Analysis to quantify intra-fraction, inter-fraction and post-treatment changes in tumor target volumes and surrounding normal organs in radiation therapy.",[388],"2026-04-30",{"date":558,"type":41},"2026-05-06",{"date":560,"type":4},"2015-01",{"date":562,"type":23},"2028-03-20",{"name":47,"class":48},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":338,"minAge":19,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":24,"phases":573,"briefSummary":574,"conditions":575,"keywords":577,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":586,"leadSponsor":588,"locationsCount":49},"100636873","fueling-labor-protein-supplementation-for-intrapartum-glucose-control-100636873","NCT07571343","Fueling Labor: Protein Supplementation for Intrapartum Glucose Control","Fueling Labor: A Pilot Randomized Controlled Trial of High-Protein Supplementation During Labor to Improve Glucose Control in Insulin-Treated Diabetes Using Continuous Glucose Monitoring","Inclusion Criteria:\n\n* Age ≥18 years\n* Singleton pregnancy\n* Gestational age ≥37 0\u002F7 weeks at time of induction\n* Diagnosis of gestational diabetes requiring insulin therapy (GDM A2) or pre-existing Type 2 diabetes managed with insulin during pregnancy\n* Admission to labor and delivery for induction of labor\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Multifetal gestation\n* Major fetal anomalies or conditions affecting neonatal glucose regulation\n* Stillbirth\n* Planned cesarean delivery\n* Inability to provide consent\n* Contraindication to oral intake (e.g., NPO status for clinical indication)\n* Known allergy or intolerance to study materials, including components of the high-protein supplement or CGM device",{"count":572,"type":23},60,[26],"The goal of this study is to learn if high-protein drinks during labor can improve blood sugar control in pregnant women with insulin-treated diabetes. It will also help us learn if this approach is acceptable and well-tolerated by patients. The main questions it aims to answer are:\n\n* Does drinking high-protein beverages during labor keep blood sugar in a healthier range compared to drinking standard clear liquids?\n* How do participants feel about drinking protein beverages during labor, and does it affect their energy levels and birth experience?\n* Is the baby less likely to have low blood sugar after birth when the mother drinks protein beverages during labor?\n\nResearchers will compare women who drink high-protein beverages to women who drink standard clear liquids (like juice, broth, and popsicles) to see if protein drinks help keep blood sugar more stable during labor.\n\nParticipants will:\n\n* Wear a small, painless glucose sensor on their arm from when labor starts until about one week after giving birth\n* Be randomly assigned to either drink a clear protein beverage every 4 hours during labor OR drink standard clear liquids as usual\n* Complete short surveys about how tired they feel during labor, their overall birth experience, and their overall experience with the glucose sensor",[576],"Diabetes During Pregnancy",[578,579,580,581,582],"Intrapartum glucose control","continuous glucose monitoring","Protein supplementation","diabetes in pregnancy","time above range","2026-04-29",{"date":558,"type":41},{"date":328,"type":23},{"date":587,"type":23},"2028-07-30",{"name":47,"class":48},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":24,"phases":597,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":49},"100550004","blood-flow-restriction-training-for-people-with-disabilities-100550004","NCT06441422","Blood Flow Restriction Training for People With Disabilities","Effectiveness of Low Load Resistance Training With Blood Flow Restriction in Individuals With Disabilities","Inclusion Criteria:\n\n* Male or female\n* Age \\> or = 18\n* English speaking\n* Able to understand and perform upper extremity exercises\n\nExclusion Criteria:\n\n* Pregnant\n* Body mass index \\>40 kg·m-2\n* Uncontrolled hypertension (\\>150\u002F90 mmHg)\n* Presence of neuromuscular junction and other muscle diseases\n* Myocardial infarction in the past 6 months\n* Unstable cardiovascular disease\n* History of an upper limb deep vein thrombosis\n* History of autonomic dysreflexia\n* Upper extremity fracture within the last 6 months",{"count":261,"type":23},[26],"A large portion of the American population live with disabilities. People with disabilities can find it difficult to perform standard exercise routines. Regular exercise is necessary to be healthy, especially as people age. Lack of exercise can lead to secondary health concerns, like loss of muscle mass, diabetes, heart attack or stroke, to name a few. For exercise to be most beneficial, a certain degree of intensity must be achieved. Low load blood flow restriction training may be able to mimic the intensity of beneficial exercise without actually exercising hard. It may be a good option for people with disabilities who find it difficult to exercise.",[600],"Weakness, Muscle",[602,603,604],"Disability","Blood flow restriction","Low load blood flow restriction training",{"date":606,"type":41},"2026-05-01",{"date":608,"type":41},"2024-12-12",{"date":610,"type":23},"2027-12-31",{"name":47,"class":48},{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":24,"phases":620,"briefSummary":621,"conditions":622,"keywords":624,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":49},"100533652","molecular-profile-related-individualized-targeted-therapy-in-resected-pancreatic-cancer-with-high-risk-of-cancer-recurrence-100533652","NCT06228599","Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence","PROTECT-PANC","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Pathologically confirmed pancreatic cancer (excluding neuroendocrine histology).\n3. Pancreatic tumor is surgically removed and\n\n   1. patient has received multimodal therapy (neoadjuvant, sandwich or adjuvant chemotherapy ± radiation) or\n   2. patient is ineligible for or refuses multimodal therapy.\n4. Patient has one of the following:\n\n   1. Post-surgical cancer antigen (CA) 19-9 elevation (\\> 35 U\u002FmL at least 6 weeks post-surgical resection) in the setting of bilirubin \\\u003C 2 mg\u002FdL (unless bilirubin elevation is consistent with Gilbert's syndrome) OR\n   2. High-risk pathological features, defined as positive surgical margin or lymph node involvement in cancer.\n5. Patient has no definitive measurable disease recurrence or metastatic disease at the time of first post-surgical imaging (in those with high-risk pathological features) or within four weeks of elevated CA 19-9 value as evidenced by appropriate imaging.\n6. Laboratory values:\n\n   1. Absolute neutrophil count (ANC) ≥ 1.0 × 109\u002FL.\n   2. Platelet count ≥ 75,000\u002Fmm\\^3 (125 × 109\u002FL).\n   3. Hemoglobin (Hgb) ≥ 8 g\u002FdL.\n   4. aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT), alanine transaminase (ALT) serum glutamate-pyruvate transaminase (SGPT) ≤ 5 × upper limit of normal range (ULN).\n7. Eastern Cooperative Oncology Group (ECOG) Performance Status \\\u003C 3.\n8. At the time of treatment, patient should be off other anti-tumor agents for at least five half-lives of the agent or three weeks from the last day of treatment, whichever is shorter.\n9. Able to swallow and retain oral medication, if needed.\n10. Pregnancy It is not known what effects matched therapy has on human pregnancy or development of the embryo or fetus. Therefore, female subjects participating in this study should avoid becoming pregnant, and male subjects should avoid impregnating a female partner. Nonsterilized female subjects of reproductive age and male subjects should use effective methods of contraception through defined periods during and after study treatment as specified below.\n\n    Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n    * Not a female of childbearing potential (FCBP), defined as all female patients that were not in post-menopause for at least one year or are surgically sterile, OR\n    * An FCBP must have a negative serum pregnancy test and agree to use at least one form of pregnancy prevention during the study for at least one month after treatment discontinuation unless otherwise noted by the agent(s) USPI, which the FCBP must follow.\n\n    Male participants: A male participant, even if surgically sterilized (i.e., status post vasectomy), must use a form of barrier pregnancy prevention approved by the investigator or treating physician during the study and for at least one month after treatment discontinuation and refrain from donating sperm during this period unless otherwise noted by the agent(s) USPI, which the male participant must follow.\n11. Patient must be presented at the Molecular Tumor Board (MTB) and agree to receive the MTB-recommended therapy.\n12. Ability to understand a written informed consent document, and the willingness to sign it.\n\n    1. Patients presented at the MTB prior to signing consent are eligible to be on study. Patients do not need to be presented again at the MTB prior to starting therapy on trial unless six months elapse between consent and start of study treatment.\n\nExclusion Criteria:\n\nA potential study subject who meets any of the following exclusion criteria is ineligible to participate in the study.\n\n1. CA 19-9 non-producers, unless high-risk pathological features present.\n2. Receiving concomitant investigational agent(s) for pancreatic ductal adenocarcinoma (PDAC).\n3. Radiographic evidence of metastatic disease.\n4. Inability to ingest study drugs by mouth.\n5. Diarrheal bowel movements \\> 6 per day postoperatively on maximal medical therapy.\n6. Patient has active, untreated, or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic intravenous therapy.\n7. Patient has undergone or planned major surgery other than diagnostic surgery (i.e., surgery done to obtain a biopsy for diagnosis without removal of an organ) within four weeks prior to Day 1 of study therapy.\n8. Patient has a history of allergy or hypersensitivity to the study drug(s) or any of the excipients.\n9. Uncontrolled concurrent illness, including, but not limited to, unstable angina pectoris, uncontrolled and clinically significant cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n10. Is pregnant or breastfeeding or any patient with childbearing potential not using adequate pregnancy prevention.",{"count":361,"type":23},[26],"This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.",[623],"Pancreas Cancer",[625,393,626],"pancreatic cancer","targeted therapy",{"date":539,"type":41},{"date":629,"type":41},"2024-02-29",{"date":631,"type":23},"2029-01-31",{"name":47,"class":48},{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":160,"phases":4,"briefSummary":643,"conditions":644,"keywords":646,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":651,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":49},"100509558","determining-individualized-cancer-therapy-in-pancreatic-cancer-100509558","NCT05914987","Determining Individualized Cancer Therapy in Pancreatic Cancer","Profile-Related Evidence Determining Individualized Cancer Therapy in Pancreatic Cancer (PREDICT-PANC)","PREDICT-PANC","Inclusion Criteria:\n\n* Age ≥18 years.\n* Pathologically confirmed pancreatic cancer.\n* Ability to understand a written informed consent document and the willingness to sign it\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Primary cancer diagnosis other than pancreatic cancer.",{"count":642,"type":23},1000,"This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.",[645],"Pancreatic Neoplasms",[647,648,649,388,650],"Mutation","Genomics","Targeted Therapy","Pancreas",{"date":539,"type":41},{"date":653,"type":41},"2023-12-04",{"date":655,"type":23},"2033-08-01",{"name":47,"class":48},""]